SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-008346 to Scilex Holding Co (SCLX, SCLXW) (CIK 0001820190) (SCLX)

Scilex Holding Co (SCLX, SCLXW) (CIK 0001820190)
Date: July 23, 2024 · CIK: 0001820190 · Accession: 0000000000-24-008346

AI Filing Summary & Sentiment

File numbers found in text: 333-280882

Date
July 23, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Scilex Holding Co (SCLX, SCLXW) (CIK 0001820190)

Letter

July 23, 2024 Jaisim Shah Chief Executive Officer & President Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Re:Scilex Holding Company Registration Statement on Form S-3 Filed July 18, 2024 File No. 333-280882 Dear Jaisim Shah: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Elizabeth A. Razzano, Esq.

Show Raw Text
July 23, 2024
Jaisim Shah
Chief Executive Officer & President
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Re:Scilex Holding Company
Registration Statement on Form S-3
Filed July 18, 2024
File No. 333-280882
Dear Jaisim Shah:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Elizabeth A. Razzano, Esq.